Scarica l'app Stockscreener
3.05
12.10%
-0.42
Dopo l'orario di chiusura:
3.03
-0.02
-0.66%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ZNTL Giù?
Forum
Previsione
Precedente Chiudi:
$3.47
Aprire:
$3.48
Volume 24 ore:
1.20M
Relative Volume:
0.61
Capitalizzazione di mercato:
$227.55M
Reddito:
-
Utile/perdita netta:
$-292.19M
Rapporto P/E:
-0.6354
EPS:
-4.8
Flusso di cassa netto:
$-208.41M
1 W Prestazione:
-24.32%
1M Prestazione:
-2.87%
6M Prestazione:
-74.73%
1 anno Prestazione:
-73.13%
Intervallo 1D:
$3.00
$3.48
Intervallo di 1 settimana:
$3.00
$4.44
Portata 52W:
$2.66
$18.07
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
Nome
Zentalis Pharmaceuticals Inc
Settore
Industria
Telefono
(858) 263-4333
Indirizzo
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Confronta ZNTL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| ZNTL | 3.05 | 227.55M | 0 | -292.19M | -208.41M | -4.80 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-07-12 | Iniziato | Cowen | Outperform |
| 2022-04-06 | Iniziato | Wells Fargo | Overweight |
| 2021-10-07 | Ripresa | Jefferies | Buy |
| 2021-09-30 | Iniziato | Stifel | Buy |
| 2021-09-29 | Iniziato | Oppenheimer | Outperform |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-01-20 | Iniziato | Wedbush | Outperform |
| 2020-09-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-08-27 | Iniziato | H.C. Wainwright | Buy |
| 2020-04-28 | Iniziato | Guggenheim | Buy |
| 2020-04-28 | Iniziato | Jefferies | Buy |
| 2020-04-28 | Iniziato | Morgan Stanley | Overweight |
| 2020-04-28 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Zentalis Pharmaceuticals Inc Borsa (ZNTL) Ultime notizie
What is HC Wainwright's Estimate for ZNTL Q3 Earnings? - MarketBeat
Leerink Partnrs Has Positive Outlook of ZNTL FY2024 Earnings - MarketBeat
Guggenheim Cuts Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target to $8.00 - MarketBeat
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Earns "Buy" Rating from HC Wainwright - MarketBeat
Wedbush Has Positive Estimate for ZNTL FY2024 Earnings - MarketBeat
Citadel Advisors LLC Adjusts Stake in Zentalis Pharmaceuticals I - GuruFocus.com
ZNTL (Zentalis Pharmaceuticals) Enterprise Value : $282.73 Mil (As of Nov. 14, 2024) - GuruFocus.com
Zentalis Pharmaceuticals Announces New Leadership and Strategy Shift - TipRanks
Zentalis Pharmaceuticals Adds New Executives as Efforts Around Azenosertib Sharpen - MarketWatch
Zentalis Pharmaceuticals Announces Executive Leadership - GlobeNewswire
Zentalis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Wealth Enhancement Advisory Services LLC Grows Stock Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
GSA Capital Partners LLP Purchases 353,384 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - MarketBeat
Zentalis Pharmaceuticals Inc (ZNTL): Worth A Small Bite At $3.81 - Stocks Register
Eventide Asset Management's Strategic Reduction in Zentalis Phar - GuruFocus.com
Vanguard Group Inc's Strategic Reduction in Zentalis Pharmaceuti - GuruFocus.com
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of "Hold" from Analysts - MarketBeat
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Immunome (NASDAQ: IMNM) Acquires Zentalis Pharmaceuticals’ Licensed Assets IMMUNOME, Inc. made a recent significant move on October 25, 2024, by acquiring Zentalis Pharmaceuticals, Inc.’s Licensed Assets. This acquisition was carried out thr - Defense World
Zentalis stock hits 52-week low at $2.82 amid market challenges - Investing.com Canada
Undervalued Opportunities: US Penny Stocks To Watch In October 2024 - Simply Wall St
State Street Corp's Strategic Reduction in Zentalis Pharmaceuticals Holdings - Yahoo Finance
Perhaps timely catching Zentalis Pharmaceuticals Inc (ZNTL) would be a good idea - SETE News
Zentalis Pharmaceuticals Inc [ZNTL] Stock sold by Insider Vultaggio Vincent for $5098.0 - Knox Daily
Several Insiders Invested In Zentalis Pharmaceuticals Flagging Positive News - Yahoo Finance
Balance Sheet Insights: Zentalis Pharmaceuticals Inc (ZNTL)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Zentalis Pharmaceuticals Inc (ZNTL)’s highs and lows: A closer look at its stock price fluctuations - US Post News
Short Interest in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Decreases By 26.2% - MarketBeat
ZNTL Shares Experience Decline in Value - Knox Daily
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives $10.78 Consensus Price Target from Brokerages - MarketBeat
A History of Outperforming Analyst Forecasts and Beating the Odds: Zentalis Pharmaceuticals Inc (ZNTL) - SETE News
Zentalis Pharmaceuticals Inc [ZNTL] Insider Vultaggio Vincent sells 1,603 Shares – Company Insider Activity - Knox Daily
Results from Zentalis Pharmaceuticals Inc (ZNTL) show risk - US Post News
Zentalis Pharmaceuticals Inc: A Year of Highs, Lows, and Market Resilience - The InvestChronicle
FMR LLC Adjusts Its Stake in Zentalis Pharmaceuticals Inc - Yahoo Finance
Stock Market Recap: Zentalis Pharmaceuticals Inc (ZNTL) Concludes at 3.37, a 5.31 Surge/Decline - The Dwinnex
Zentalis Pharmaceuticals executive sells over $5,000 in company stock By Investing.com - Investing.com Canada
Zentalis Pharmaceuticals executive sells over $5,000 in company stock - Investing.com India
ZNTL’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle
We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Needs To Drive Business Growth Carefully - Simply Wall St
Zentalis (ZNTL) Plunges More Than 70% in 3 Months: Here's Why - MSN
Recent Insider Activity Could Benefit Zentalis Pharmaceuticals Inc (ZNTL) - Knox Daily
A Look at Zentalis Pharmaceuticals Inc (ZNTL) Shares in the Recent Past Indicates Growth - SETE News
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Holdings Raised by Renaissance Technologies LLC - MarketBeat
Results from Zentalis Pharmaceuticals Inc (ZNTL) show potential - US Post News
Zentalis Pharma (NASDAQ:ZNTL) Stock Quotes, Forecast and News Summary - Benzinga
Decheng Capital LLC Has $12.56 Million Stock Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - MarketBeat
Holdings of Zentalis Pharmaceuticals Inc (ZNTL) are aligned with the stars - SETE News
Analyzing Ratios: Zentalis Pharmaceuticals Inc (ZNTL)’s Financial Story Unveiled - The Dwinnex
Intech Investment Management LLC Raises Position in Zscaler, Inc. (NASDAQ:ZS) - MarketBeat
Beyond The Numbers: 7 Analysts Discuss Zevra Therapeutics Stock - Benzinga
Zentalis Pharmaceuticals Inc Azioni (ZNTL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.66%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):